<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001493152-25-012120</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Ong Yee Lung -->
          <cik>0002081473</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/01/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001130166</issuerCik>
        <issuerName>Cyclacel Pharmaceuticals, Inc.</issuerName>
        <issuerCusip>23254L876</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>Level 10, Tower 11, Avenue 5,</com:street1>
          <com:street2>No. 8 Jalan Kerinchi,</com:street2>
          <com:city>Kuala Lumpur</com:city>
          <com:stateOrCountry>N8</com:stateOrCountry>
          <com:zipCode>07922</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Ong Yee Lung</reportingPersonName>
      <citizenshipOrOrganization>N8</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>872000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>872000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>872000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>20.76</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>The reporting person's ownership consists of (i) 218,000 shares of common stock, (ii) 218,000 series A warrants to purchase shares of common stock, (iii) 218,000 series B warrants to purchase shares of common stock, and (iv) 218,000 series C warrants to purchase shares of common stock (the series A warrants, series B warrants and series C warrants, collectively, the "Warrants")</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Cyclacel Pharmaceuticals, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Ong Yee Lung</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>9 JALAN LAWA 3 TAMAN PELANGI INDAH ULU TIRAM 81800 JOHOR MALAYSIA</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Malaysia</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>872,000</amountBeneficiallyOwned>
        <classPercent>20.76%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>872,000</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>872,000</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Form of Amended and Restated Series A Common Stock Warrant

Form of Amended and Restated Series B Common Stock Warrant

Form of Amended and Restated Series C Common Stock Warrant

sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-1.htm

sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-2.htm

sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-3.htm

sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-4.htm</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Ong Yee Lung</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Ong Yee Lung</signature>
        <title>Ong Yee Lung</title>
        <date>09/01/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>

</edgarSubmission>
